These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 8473389)

  • 1. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity.
    Cordido F; Peñalva A; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1993 Apr; 76(4):819-23. PubMed ID: 8473389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man.
    Peñalva A; Carballo A; Pombo M; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1993 Jan; 76(1):168-71. PubMed ID: 8421084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression.
    Cordido F; Peino R; Peñalva A; Alvarez CV; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1996 Mar; 81(3):914-8. PubMed ID: 8772550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6, and pyridostigmine in normal and obese subjects.
    Cordido F; Peñalva A; Peino R; Casanueva FF; Dieguez C
    Metabolism; 1995 Jun; 44(6):745-8. PubMed ID: 7783658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentiates the response to other GH-releasing stimuli.
    Peino R; Cordido F; Peñalva A; Alvarez CV; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1996 Mar; 81(3):909-13. PubMed ID: 8772549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
    Cordido F; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level.
    Popovic V; Damjanovic S; Micic D; Djurovic M; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1995 Mar; 80(3):942-7. PubMed ID: 7883854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood.
    Micic D; Popovic V; Kendereski A; Macut D; Casanueva FF; Dieguez C
    Clin Endocrinol (Oxf); 1995 Feb; 42(2):191-4. PubMed ID: 7734029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of growth hormone release after the combined administration of GHRH and GHRP-6 in patients with Cushing's syndrome.
    Leal-Cerro A; Pumar A; Garcia-Garcia E; Dieguez C; Casanueva FF
    Clin Endocrinol (Oxf); 1994 Nov; 41(5):649-54. PubMed ID: 7828354
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Absence of growth hormone (GH) secretion after the administration of either GH-releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection.
    Pombo M; Barreiro J; Peñalva A; Peino R; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1995 Nov; 80(11):3180-4. PubMed ID: 7593423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of endogenous cholinergic tone and alpha-adrenergic pathways on growth hormone responses to His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 in the dog.
    Muruais J; Peñalva A; Dieguez C; Casanueva FF
    J Endocrinol; 1993 Aug; 138(2):211-8. PubMed ID: 8228729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growth hormone (GH) secretion in active acromegaly after the combined administration of GH-releasing hormone and GH-releasing peptide-6.
    Popovic V; Damjanovic S; Micic D; Petakov M; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1994 Aug; 79(2):456-60. PubMed ID: 8045963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of His-dTrp-Ala-Trp-dPhe-Lys-NH2 (GHRP-6)-induced GH secretion in the rat.
    Mallo F; Alvarez CV; Benitez L; Burguera B; Coya R; Casanueva FF; Dieguez C
    Neuroendocrinology; 1993; 57(2):247-56. PubMed ID: 8510800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of growth hormone-releasing peptide 1-6 on GH secretion-stimulated by GHRH and pyridostigmine in lambs.
    Rico M; Rueda V; Lorenzo MT; Núñez A; De la Cruz LF
    J Physiol Biochem; 1998 Jun; 54(2):67-76. PubMed ID: 9858126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth hormone (GH)-releasing peptide stimulation of GH release from human somatotroph adenoma cells: interaction with GH-releasing hormone, thyrotropin-releasing hormone, and octreotide.
    Renner U; Brockmeier S; Strasburger CJ; Lange M; Schopohl J; Müller OA; von Werder K; Stalla GK
    J Clin Endocrinol Metab; 1994 May; 78(5):1090-6. PubMed ID: 8175966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low hexarelin dose and pyridostigmine have additive effect and potentiate to the same extent the GHRH-induced GH response in man.
    Arvat E; Di Vito L; Ramunni J; Gianotti L; Giordano R; Deghenghi R; Camanni F; Ghigo E
    Clin Endocrinol (Oxf); 1997 Oct; 47(4):495-500. PubMed ID: 9404449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. On the actions of the growth hormone-releasing hexapeptide, GHRP.
    Bowers CY; Sartor AO; Reynolds GA; Badger TM
    Endocrinology; 1991 Apr; 128(4):2027-35. PubMed ID: 2004615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone.
    Bowers CY; Reynolds GA; Durham D; Barrera CM; Pezzoli SS; Thorner MO
    J Clin Endocrinol Metab; 1990 Apr; 70(4):975-82. PubMed ID: 2108187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects.
    Cordido F; Dieguez C; Casanueva FF
    J Clin Endocrinol Metab; 1990 May; 70(5):1361-70. PubMed ID: 2159483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of enhancement of endogenous cholinergic tone with pyridostigmine on the dose-response relationships of growth hormone (GH)-releasing hormone-induced GH secretion in normal subjects.
    Peñalva A; Muruais C; Casanueva FF; Dieguez C
    J Clin Endocrinol Metab; 1990 Feb; 70(2):324-7. PubMed ID: 2105328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.